RE:Drug cost a key factor to oncologistsScienceFirst wrote: Another thing in our favor. Our only 2-doses treatment should give us enough of room to displace competition on the price aspect.
Gene therapy like Ferring's recently approved Adstiladrin will be harder to sell because it price tag will be high.
US oncologists see cost as biggest barrier to new cancer drug uptake, with cell, gene therapy expertise lagging: survey
https://www.fiercepharma.com/marketing/us-oncologists-see-cost-biggest-barrier-new-cancer-drug-uptake-cell-gene-therapy
Oncologists in the U.S. see pricing as the largest hurdle for patients when it comes to accessing new cancer therapies, while many are also struggling to keep up with the pace of new cell and gene therapies.
That’s according to a new survey out this month from healthcare research firm Sermo, which surveyed more than 300 oncologists.
This is going to be great!!! Rutherrin (Enhanced Radiation Therapy Platform Technology or Technology for Innovation in Radiation Oncology) Non-Small Cells Lung Cancer (NSCLC) Late Preclinical Stage & Rutherrin (Enhanced Radiation Therapy Platform Technology or Technology for Innovation in Radiation Oncology) Glioblastoma Multiforme (GBM) Late Preclinical Stage